nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Anxiety/Stress-Related Disorders"

 

Meta-Analysis: What Treatments Are Safe and Effective in Pediatric Anxiety?
September 18, 2017   

A recent meta-analysis compared the effectiveness of cognitive behavioral therapy (CBT) and pharmacotherapy for childhood anxiety disorders...
 Continue reading (Members only)
SSRIs, SNRIs Show Small But Significant Benefit for Children and Adolescents With Common Mental Illnesses
September 11, 2017   

There continues to be much debate over the utility and risk-to-benefit ratio of antidepressant use within the pediatric population. In the present meta-analysis, Locher and colleagues investigated the safety and efficacy of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)...
 Continue reading (Members only)
Using Brain Patterns to Predict Treatment Response in PTSD
August 18, 2017   

In a recent study, patients with posttraumatic stress disorder (PTSD) underwent functional magnetic resonance imaging (fMRI) while completing three tasks assessing emotional reactivity and regulation...
 Continue reading (Members only)
Pediatric Suicide: Age Matters
June 20, 2017   

In the United States, the 4th leading cause of death among children age 5-14 years is suicide. In this study, Peyre and colleagues compared risk factors for suicide attempt in children and adolescents...
 Continue reading
FDA Approves Trials for MDMA as Treatment for PTSD
December 14, 2016   

As many as 24.5% of Iraq and Afghanistan veterans may suffer with posttraumatic stress disorder (PTSD), a disorder characterized by re-experiencing, avoidance, arousal, and changes to mood and cognition. Available pharmacological treatments approved for treating PTSD (sertraline and paroxetine) have very limited efficacy...
 Continue reading
FDA Alert: Boxed Warning for Combined Use of Opioids and Benzodiazepines
September 2, 2016   

The US FDA is added a boxed warning to the labels of opioid pain and opioid cough medications and benzodiazepines regarding the increased risk of central nervous system (CNS) depressant effects when these medications are used together...
 Continue reading (Members only)
Alert: Counterfeit Alprazolam
August 24, 2016   

US experts warn that counterfeit versions of the benzodiazepine alprazolam (Xanax, Pharmacia and Upjohn) that contain the highly potent opioid fentanyl are being sold online, placing people at risk for serious adverse events, including death...
 Continue reading (Members only)
Study Suggests Increased Risk of Major Birth Defects With Pregabalin
June 17, 2016   

There is often great concern over the use of psychotropic agents in women who are pregnant or who may become pregnant and knowledge of any particular agent's reproductive toxicity are largely based on animal studies. In this prospective study of 820 pregnancies (164 pregabalin-exposed and 656 epileptic-free controls), Winterfeld et al. found an increased risk...
 Continue reading (Members only)
News from the 2016 American Psychiatric Association Annual Meeting
June 10, 2016   

Here are a few highlights from the poster sessions at the 166th annual American Psychiatric Association meeting.
 Continue reading (Members only)
Safety of Antidepressants During Different Stages of Pregnancy: New Data
March 25, 2016   

In one recent study, exposure to a serotonin norepinephrine reuptake inhibitor (SNRI) during late pregnancy appeared to significantly increase the risk of postpartum hemorrhaging, while another study showed that taking antidepressants during pregnancy does not appear to increase the risk of having a baby with congenital heart abnormalities.
 Continue reading (Members only)
12
Top of Page